Bristol-Myers Squibb Co (LTS:0R1F)
$ 54.48 -1.095 (-1.97%) Market Cap: 109.81 Bil Enterprise Value: 153.11 Bil PE Ratio: 0 PB Ratio: 6.41 GF Score: 84/100

Bristol-Myers Squibb Co at Citi BioPharma Conference Transcript

Sep 08, 2022 / 12:50PM GMT
Release Date Price: $68.49 (+0.40%)
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

[Welcome] to the Bristol-Myers session. So delighted to introduce our guests from Bristol-Myers Squibb today. We have Adam Lenkowsky, who's Head of U.S. Commercialization. We've got Roland Chen, who is Head of Cardiovascular Development at Bristol-Myers. We've also got Tim Powers in the audience, who's Head of IR. So thank you all for joining us today.

Adam Lenkowsky
Bristol-Myers Squibb Company - Head of U.S. Oncology

Thanks for having us.

Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

My pleasure. So maybe to start with milvexian segue to [dacarabasitenib], and then we'll ramp up the rest of it in the second half of the conversation. If anyone in the room has a question, then please don't be shy, raise a hand, and we're happy to take your question.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot